Ensysce Biosciences, Inc. - Common Stock (ENSC)

Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.

~ Positive Enrollment Progress and Safety Data ~

~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~

~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to commence 1H 2025 ~

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December 20, 2024, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). Ensysce had previously regained compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1). As a result, the Company has met all requirements outlined in the Nasdaq Hearings Panel decision dated November 5, 2024, and Ensysce common stock will continue trading on The Nasdaq Capital Market.

~ Supply Chain Now Fully Secure for PF614-MPAR ~

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~

~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on Friday, December 6, 2024, effective at 12:01 a.m. Eastern Time, it will implement a 1-for-15 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on December 6, 2024, under its current trading symbol "ENSC". The new CUSIP number of the Company's common stock following the reverse stock split will be 293602 504.

Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR

SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to November 14, 2024, to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1) as of September 30, 2024, with filing of its Form 10-Q. Additionally, the Company received an extension toDecember 19, 2024, to evidence compliance with the Minimum Bid Price in Listing Rule 5550(a)(2), all other applicable requirements and the Company's satisfaction of certain other interim conditions.